![](https://www.mll.com/media/pages/publikationen/b6aab0901a-1644219631/brandi-redd-ajtiw00qqti-unsplash-1600x-q80-1600x-q99.webp)
Publications
Our research findings are published in international, peer-reviewed journals and feature in conference talks and lectures, as well as in poster presentations and at scientific events.
MLL frequently hosts international research cooperation directly: For
instance through exchange programs, our test procedures and data
repositories, but also by allowing guest researchers to shadow the work
of our facility and by sitting on national and international work
groups.
We also support research institutions around the world to
produce new insight in the field of leukemia diagnostics and emergence,
as well as in the rollout of new procedures and applications for routine
diagnostics in the facilities themselves.
Overview of our publications
Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma.
John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, Leipold AM, Steinhardt MJ, Zhou X, Žihala D, Anilkumar Sithara A, Mersi J, Waldschmidt JM, Riedhammer C, Kadel SK, Truger M, Werner RA, Haferlach C, Einsele H, Kretzschmar K, Jelínek T, Rosenwald A, Kortüm KM, Riedel A, Rasche L. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024.
Read moreFlow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines.
Monaghan SA, Eck S, Bunting S, Dong XX, Durso RJ, Gonneau C, Hays A, Illingworth A, League SC, Linskens E, McCausland M, McCloskey TW, Rolf N, Shi M, Wallace PK, Litwin V, Kern W, Deeb G, Nash V, Olteanu H. Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines . Cytometry B Clin Cytom. 2024.
Read moreInfluence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al-Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D. Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion. Blood. 2024.
Read moreImplementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain.
Devitt KA, Kern W, Kajstura MA, Holl EK, Hays AL, Hedley BD, Gonneau C, Jellison ER, McCloskey TW, Mishra S, Rebeles J, Ouseph MM. Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain. Cytometry B Clin Cytom. 2024.
Read moreSubunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
Jann JC, Hergott CB, Winkler M, Liu Y, Braun B, Charles A, Copson KM, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer ES, Wadleigh M, Stone RM, DeAngelo DJ, Garcia JS, Haferlach T, Lindsley RC, Luskin MR, Stahl M, Tothova Z. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia. 2024.
Read moreFBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
Sperk A, Gabriel A, Koch D, Augsburger A, Sanchez V, Brockelt D, Öllinger R, Engleitner T, Giansanti P, Ludwig R, Auf der Maur P, Walter W, Haferlach T, Jeremias I, Rad R, Steigenberger B, Kuster B, Eichner R, Bassermann F. FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells. Leukemia. 2024.
Read moreCharacterization of Cases with the Rare Cytogenetic Abnormality i(7)(p10) Reveals an Association with IDH2 Mutated AML.
Stengel A, Hörst K, Kühn C, Meggendorfer M, Kern W, Haferlach T, Haferlach C. Characterization of Cases with the Rare Cytogenetic Abnormality i(7)(p10) Reveals an Association with IDH2 Mutated AML. Blood Adv. 2024.
Read more